Axsome Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Axsome Therapeutics Inc AXSM.OQ reported a quarterly adjusted loss of $1.54​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-2.08. The mean expectation of seventeen analysts for the quarter was for a loss of $1.02 per share. Wall Street expected results to range from $-1.32 to -61 cents per share.

• Revenue rose 66% to $118.77 million from a year ago; analysts expected $117.64 million.

• Axsome Therapeutics Inc's reported EPS for the quarter was a loss of $1.54​.

• The company reported a quarterly loss of $74.91 million.

• Axsome Therapeutics Inc shares had risen by 55.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 7.1% in the last three months.​

• In the last 30 days, five analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Axsome Therapeutics Inc is $151.50

This summary was machine generated from LSEG data February 18 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)